Eyepoint Pharmaceuticals’ (EYPT) “Neutral” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their neutral rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research note released on Monday, MarketBeat reports. Chardan Capital currently has a $5.00 price objective on the stock, down from their prior price objective of $65.00.

A number of other analysts also recently issued reports on EYPT. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective for the company. HC Wainwright dropped their target price on shares of Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Royal Bank Of Canada reduced their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Cantor Fitzgerald raised their price target on shares of Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Finally, Guggenheim restated a “buy” rating and issued a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Eyepoint Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $28.11.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $6.30 on Monday. The company has a market capitalization of $543.12 million, a PE ratio of -1.68 and a beta of 1.76. The business has a fifty day moving average price of $12.85 and a two-hundred day moving average price of $13.49. Eyepoint Pharmaceuticals has a 1 year low of $3.95 and a 1 year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Sell-side analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in EYPT. Rhumbline Advisers increased its position in shares of Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock valued at $906,000 after purchasing an additional 9,548 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Eyepoint Pharmaceuticals by 57.8% during the 2nd quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock valued at $636,000 after buying an additional 24,752 shares in the last quarter. Invesco Ltd. lifted its position in Eyepoint Pharmaceuticals by 199.8% in the 2nd quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock worth $1,212,000 after buying an additional 85,824 shares during the last quarter. Raymond James Financial Inc. lifted its position in Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after buying an additional 1,177 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Eyepoint Pharmaceuticals by 9.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock worth $63,988,000 after buying an additional 600,000 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said the primary-endpoint miss was largely attributable to nine patients—approximately 4% of the study population—who experienced vision loss unrelated to wet AMD. The company also pointed to favorable secondary endpoints, reduced treatment burden and durable disease control, which could preserve the broader DURAVYU investment case. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Positive Sentiment: Upcoming LUCIA Phase 3 data, expected in the fourth quarter of 2026, is now a major catalyst. A positive result could help revive confidence in DURAVYU and partially offset the LUGANO failure.
• Positive Sentiment: Citigroup maintained a buy rating while reducing its price target to $17, implying substantial potential upside if the remaining clinical program succeeds.
• Neutral Sentiment: Unusually active options trading included the purchase of about 3,011 call contracts, above average volume. This may reflect speculative positioning around the stock’s volatility and upcoming clinical catalysts rather than a fundamental improvement.
• Negative Sentiment: The LUGANO trial’s failure to achieve its primary endpoint sharply weakened the clinical and regulatory case for DURAVYU in wet AMD. Analysts have questioned whether the secondary results can compensate for the failed head-to-head outcome. EYPT Stock Plunges After Duravyu Misses Phase III Eye Disease Goal
• Negative Sentiment: Royal Bank of Canada downgraded EyePoint to hold and Chardan Capital cut its rating to neutral; both cited $5 price targets. Cantor Fitzgerald also moved to neutral, while Jefferies lowered its expectations. Chardan, JPMorgan and HC Wainwright otherwise maintained neutral-type views.
• Negative Sentiment: The stock reached a new 12-month low as investors reassessed EyePoint’s valuation, execution risk and dependence on future clinical data. EyePoint Hits New 12-Month Low After Analyst Downgrade

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.